AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28627980 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-intervention group (specialist-based, lifestyle modification and pharmacological treatment)
Number of subjects: 120
Study 28627980 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (GP-provided care)
Number of subjects: 120
Study 26402011 — intervention group
Group type: EXPERIMENTAL
Intervention: ST101 (10, 60, or 120 mg QD)
Number of subjects: 210
Study 26402011 — intervention group
Group type: EXPERIMENTAL
Intervention: ST101 (120 mg QD)
Number of subjects: 210
Study 26402011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 23528656 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy (CVC)
Number of subjects: 110
Study 21267543 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy intervention
Number of subjects: 40
Study 21267543 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home-based rehabilitation
Number of subjects: 40
Study 19553296 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/d for infants aged 2 wk to 6 mo; 10 mg/d for infants aged >6 mo)
Number of subjects: 2052
Study 19553296 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2052
Study 19553296 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2052
Study 16892419 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (maximum 60 mg by week 7)
Number of subjects: 70
Study 16892419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16892419 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 70
Study 15469648 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐38 fermented milk
Number of subjects: 8
Study 15469648 — intervention group
Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 8
Study 11289332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide (1,600 microg daily)
Number of subjects: 60
Study 11289332 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone (1 mg/kg daily) plus medium-dose inhaled budesonide (800 microg daily)
Number of subjects: 60
Study 11289332 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide
Number of subjects: 60
Study 11289332 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone plus medium-dose inhaled budesonide
Number of subjects: 60
Study 9710866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol at 30 degrees/s
Number of subjects: 20
Study 9710866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol at 150 degrees/s
Number of subjects: 20
Study 8038614 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test (RAST)
Number of subjects: 27
Study 8038614 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative responses of peripheral blood mononuclear cells (PBMCs) to ovalbumin
Number of subjects: 27
Study 2647896 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oral morphine sulfate (MSC) dosed at 8-, 10-, and 12-hour intervals
Number of subjects: 0
Study 2647896 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) dosed every four hours
Number of subjects: 0
Study 2647896 — intervention group
Group type: COMPARATOR
Intervention: Prestudy analgesics
Number of subjects: 0
Study 29260713 — intervention group
Group type: COMPARATOR
Intervention: bare metal stent implantation
Number of subjects: 1498
Study 29260713 — intervention group
Group type: COMPARATOR
Intervention: everolimus-eluting stent implantation
Number of subjects: 1498
Study 29055383 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) collagen microspheres
Number of subjects: 0
Study 26177074 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrrolate (27.5/15.6 μg twice daily)
Number of subjects: 2038
Study 26177074 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol (27.5 μg twice daily)
Number of subjects: 2038
Study 26177074 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (15.6 μg twice daily)
Number of subjects: 2038
Study 26177074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2038
Study 23262997 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 250
Study 23262997 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus primaquine
Number of subjects: 250
Study 23262997 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 20233822 — intervention group
Group type: COMPARATOR
Intervention: 70.2 Gy of combined photon and proton radiation
Number of subjects: 393
Study 20233822 — intervention group
Group type: EXPERIMENTAL
Intervention: 79.2 Gy of combined photon and proton radiation
Number of subjects: 393
Study 19043376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone resorption and formation markers (CTX and OC)
Number of subjects: 320
Study 19043376 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of CTX and OC levels
Number of subjects: 320
Study 16875154 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg daily for 12 months)
Number of subjects: 32
Study 16875154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 12947128 — intervention group
Group type: EXPERIMENTAL
Intervention: 570 kcal carbohydrate rich supplement
Number of subjects: 85
Study 12947128 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive placebo
Number of subjects: 85
Study 10803445 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced QTc interval changes (prolongation by > or = 20 ms) in Group 2 (7 patients)
Number of subjects: 20
Study 10803445 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced QTc interval changes (prolongation by < 20 ms or shortening) in Group 1 (13 patients)
Number of subjects: 20
Study 10803445 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 20
Study 8668288 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam cinnamate 30 mg tablets (Sinartrol), 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Number of subjects: 60
Study 8668288 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam cinnamate 20 mg tablets, 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Number of subjects: 60
Study 2053016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 to 220 mcg/kg, five single oral doses, one every six months)
Number of subjects: 83
Study 2053016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearance to ivermectin)
Number of subjects: 83
Study 7379443 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 12
Study 7379443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30772863 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) administered by paramedics
Number of subjects: 11
Study 30772863 — intervention group
Group type: COMPARATOR
Intervention: Usual care (most commonly morphine)
Number of subjects: 11
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of sweets
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional consumption of sweets
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly consumption of carbonated beverages
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of carbonated beverages
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly consumption of energy drinks
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of energy drinks
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with age
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with carbonated beverages
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with energy drinks
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with high fat food
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with BMI
Number of subjects: 725
Study 28917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of carbonated beverages with energy drinks
Number of subjects: 725
Study 25772954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (direct calls every 15 days for 4 months)
Number of subjects: 440
Study 25772954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 440
Study 25772954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile phone contacts, examined in clinic)
Number of subjects: 440
Study 23672442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 150
Study 23672442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 150
Study 23672442 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 150
Study 21867490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (MIS)
Number of subjects: 0
Study 21867490 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet only)
Number of subjects: 0
Study 19033683 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (t‐PA)
Number of subjects: 100
Study 19033683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18167250 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA 600 mg/d in normal saline 250 ml given by intravenous drip infusion once a day for 14 days
Number of subjects: 95
Study 18167250 — intervention group
Group type: COMPARATOR
Intervention: Radix salviae 20 ml by intravenous drip infusion once a day for 14 days
Number of subjects: 95
Study 15156419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale)
Number of subjects: 538
Study 11869322 — intervention group
Group type: COMPARATOR
Intervention: Handsewn esophagogastric anastomosis
Number of subjects: 5
Study 9703298 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg of estradiol daily
Number of subjects: 126
Study 9703298 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg of estradiol daily
Number of subjects: 126
Study 9703298 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg of estradiol daily
Number of subjects: 126
Study 9703298 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol
Number of subjects: 126
Study 9703298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 8020522 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 150 mgI/ml
Number of subjects: 40
Study 8020522 — intervention group
Group type: COMPARATOR
Intervention: iopamidol 150 mgI/ml
Number of subjects: 40
Study 2644144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (7.5 mg.kg‐1.day‐1)
Number of subjects: 70
Study 2644144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 947969 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline sulfate orally
Number of subjects: 10
Study 947969 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 10
Study 947969 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 10
Study 31775014 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-yogurt bundle consisting of favorite yogurt products
Number of subjects: 0
Study 31775014 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-yogurt bundle consisting of three different yogurt products
Number of subjects: 0
Study 31775014 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual discrimination task on food bundles
Number of subjects: 0
Study 31701526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention for substance misuse prevention
Number of subjects: 1488
Study 27755433 — intervention group
Group type: COMPARATOR
Intervention: Postoperative 40 mg bromelain every 6 hours for 6 days (Group B)
Number of subjects: 84
Study 27755433 — intervention group
Group type: COMPARATOR
Intervention: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection (Group C)
Number of subjects: 84
Study 27755433 — intervention group
Group type: COMPARATOR
Intervention: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection plus postoperative 40 mg bromelain every 6 hours for 6 days (Group D)
Number of subjects: 84
Study 24633493 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage(®) 500 mg) 1 tablet twice daily
Number of subjects: 40
Study 24633493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (Januvia(®) 100 mg) 1 tablet/day
Number of subjects: 40
Study 24286509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg biweekly)
Number of subjects: 212
Study 24286509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg monthly)
Number of subjects: 212
Study 24286509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 21736768 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched virgin olive oil (EVOO) (961·17 mg/kg oil)
Number of subjects: 13
Study 21736768 — intervention group
Group type: COMPARATOR
Intervention: Control virgin olive oil (VOO) (288·89 mg/kg oil)
Number of subjects: 13
Study 19423079 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 16
Study 19423079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 16
Study 17443133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin 96 mg/day orally
Number of subjects: 22
Study 17443133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14594866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of carbohydrates (CHO)
Number of subjects: 16
Study 14594866 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo drink (Pla)
Number of subjects: 16
Study 11439385 — intervention group
Group type: EXPERIMENTAL
Intervention: sALS
Number of subjects: 59
Study 11439385 — intervention group
Group type: EXPERIMENTAL
Intervention: chronic peripheral neuropathies
Number of subjects: 59
Study 11439385 — intervention group
Group type: COMPARATOR
Intervention: control subjects
Number of subjects: 59
Study 11439385 — intervention group
Group type: EXPERIMENTAL
Intervention: sALS and chronic peripheral neuropathies
Number of subjects: 59
Study 9682661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich second meal
Number of subjects: 6
Study 9682661 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat second meal
Number of subjects: 6
Study 9682661 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 6
Study 9682661 — intervention group
Group type: COMPARATOR
Intervention: Nothing by mouth
Number of subjects: 6
Study 7904978 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp with somatostatin (250 micrograms/hr)
Number of subjects: 12
Study 7904978 — intervention group
Group type: COMPARATOR
Intervention: Control clamp without somatostatin
Number of subjects: 12
Study 2599691 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 86
Study 2599691 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 86
Study 2599691 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled water
Number of subjects: 86
Study 766164 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren (diclofenac sodium)
Number of subjects: 60
Study 766164 — intervention group
Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 60
Study 31087530 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) exercise for 6 months
Number of subjects: 25
Study 30208251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐conjugated anthraquinone
Number of subjects: 0
Study 30208251 — intervention group
Group type: COMPARATOR
Intervention: Meta‐connected dihydroxyanthracene
Number of subjects: 0
Study 26625709 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D-fortified snack bar (2000 mg/d Ca and 25 µg/d vitamin D) consumed 2 snack bars/d for 9 weeks
Number of subjects: 152
Study 26625709 — intervention group
Group type: COMPARATOR
Intervention: Placebo snack bar (without Ca/vitamin D) consumed 2 snack bars/d for 9 weeks
Number of subjects: 152
Study 24166866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 400 IU
Number of subjects: 198
Study 24166866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU
Number of subjects: 198
Study 24166866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1600 IU
Number of subjects: 198
Study 24166866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2400 IU
Number of subjects: 198
Study 24166866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 22431837 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d of vitamin E (α‐tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α‐lipoic acid (E/C/ALA)
Number of subjects: 78
Study 22431837 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of coenzyme Q 3 times/d
Number of subjects: 78
Study 22431837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 19192127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 547
Study 19192127 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group <34 years
Number of subjects: 547
Study 19192127 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group >=34 years
Number of subjects: 547
Study 19192127 — intervention group
Group type: COMPARATOR
Intervention: All medication arms
Number of subjects: 547
Study 17621652 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic navigation system (MNS) guidewires
Number of subjects: 6
Study 17621652 — intervention group
Group type: COMPARATOR
Intervention: Standard guidewire (SG) techniques
Number of subjects: 6
Study 17469417 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 0
Study 11953630 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 62
Study 11953630 — intervention group
Group type: COMPARATOR
Intervention: Conservative rehabilitation
Number of subjects: 62
Study 9829111 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD with low cognitive demand
Number of subjects: 24
Study 9829111 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD with medium cognitive demand
Number of subjects: 24
Study 9829111 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD with high cognitive demand
Number of subjects: 24
Study 9829111 — intervention group
Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 24
Study 7620956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch ePTFE grafts
Number of subjects: 37
Study 7620956 — intervention group
Group type: COMPARATOR
Intervention: Standard ePTFE grafts
Number of subjects: 37
Study 7620956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 2709180 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm perineal pack
Number of subjects: 90
Study 2709180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold perineal pack
Number of subjects: 90
Study 2709180 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm sitz bath
Number of subjects: 90
Study 1101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 0.5% and 1%
Number of subjects: 11
Study 1101606 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% and 0.5%
Number of subjects: 11
Study 1101606 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 11
Study 1101606 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 11
Study 31562796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 31562796 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 29035703 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity intervention
Number of subjects: 151
Study 29035703 — intervention group
Group type: COMPARATOR
Intervention: Repeated contact control
Number of subjects: 151
Study 26253612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 4910
Study 26253612 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 4910
Study 23680176 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMBA
Number of subjects: 60
Study 23680176 — intervention group
Group type: COMPARATOR
Intervention: DC
Number of subjects: 60
Study 23680176 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 21530317 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 40 ppm
Number of subjects: 150
Study 21530317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent concentration of nitrogen)
Number of subjects: 150
Study 18278696 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (ebm) implementation in oncology
Number of subjects: 0
Study 18278696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer registries
Number of subjects: 0
Study 18278696 — intervention group
Group type: COMPARATOR
Intervention: Controlled clinical trials
Number of subjects: 0
Study 16497685 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg perindopril
Number of subjects: 12218
Study 16497685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study 12867351 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 190
Study 12867351 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 190